Our vision
We are driven by a conviction: the only scientific research that matters is the one which brings tangible benefits to society.
Therefore, we strive to bring the promise of tissue regeneration into reality by transforming our RGTA® expertise into efficient, safe and widely adopted solutions.
Our roots
As a French biotechnology company, we are dedicated to developing tissue regeneration solutions using matrix therapy to enhance the quality of life of patients affected by dermatological or neurological conditions.
Our history
OTR3 was founded by two renowned biologists, Prof. Denis Barritault and Prof. Jean-Pierre Caruelle.
Building on their pioneering research on growth factors (including FGF and the discovery of HARP/PTN), as well as their long-term medical and industrial vision, they invented and patented the RGTA® (ReGeneraTing Agents) technology, a new therapeutic class based on heparan sulfate mimetics.
Our executive committee
OTR3’s executive committee is composed of members with diverse and complementary expertise, including academic and medical backgrounds across the pharmaceutical and cosmetic industries.
Steering committee
Our steering committee, composed of renowned professionals, advises the OTR3 team on scientific, strategic, and business matters.
